Centenial Surgic

  • Market Cap: Micro Cap
  • Industry: Healthcare Services
  • ISIN: INE405H01018
  • NSEID:
  • BSEID: 531380
INR
84.50
-2.49 (-2.86%)
BSENSE

Mar 23

BSE+NSE Vol: 128

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

128 (210.68%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

46.89%

Who are the top shareholders of the Centenial Surgic?

06-Jun-2025

The top shareholders of Centenial Surgic are Vijay Kalidas Majrekar with 22.62%, and Kartik Shyam Kingar with 16.7%. Individual investors own a combined 50.29%, with no institutional holdings reported.

The top shareholders of Centenial Surgic include Vijay Kalidas Majrekar, who holds the highest promoter stake at 22.62%. The highest public shareholder is Kartik Shyam Kingar, with a holding of 16.7%. Additionally, individual investors collectively own 50.29% of the company. There are no institutional holdings from mutual funds or foreign institutional investors.

View full answer

What does Centenial Surgic do?

06-Jun-2025

Centenial Surgical Suture Ltd manufactures and sells surgical sutures in India, classified as a micro-cap company. As of March 2025, it reported net sales of 13 Cr and a net loss of 1 Cr, with a market cap of Rs 54 Cr.

Overview: <BR>Centenial Surgical Suture Ltd is engaged in the manufacture and sale of surgical sutures, operating within the healthcare services industry and classified as a micro-cap company.<BR><BR>History: <BR>Incorporated in 1995, Centenial Surgical Suture has been involved in the surgical suture market in India. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 13 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 54 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.39 <BR>Return on Equity: -5.20% <BR>Price to Book: 1.77<BR><BR>Contact Details: <BR>Address: Plot No F-29, MIDC Industrial Area Murbad Thane Maharashtra : 421401 <BR>Tel: 91-2524-222905/222906 <BR>Email: admin@centenialindia.com <BR>Website: http://www.centenialindia.com

View full answer

Who are in the management team of Centenial Surgic?

06-Jun-2025

As of March 2022, the management team of Centenial Surgic includes Vijay Majrekar (Chairman/Executive Director), Anuradha Kashikar (Executive Director/Whole Time Director), Devraj T Poojary (Executive Director/Whole Time Director), and four Independent Non-Executive Directors: B S Limaye, Sunil C Modi, Jagadish B Shetty, and N M Vora.

As of March 2022, the management team of Centenial Surgic includes the following individuals:<BR><BR>1. Vijay Majrekar - Chairman / Executive Director<BR>2. Anuradha Kashikar - Executive Director / Whole Time Director<BR>3. Devraj T Poojary - Executive Director & Whole Time Director<BR>4. B S Limaye - Independent Non-Executive Director<BR>5. Sunil C Modi - Independent Non-Executive Director<BR>6. Jagadish B Shetty - Independent Non-Executive Director<BR>7. N M Vora - Independent Non-Executive Director<BR><BR>These members play various roles in the company's governance and management structure.

View full answer

Has Centenial Surgic declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Centenial Surgic?

03-Jun-2025

Centenial Surgic's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Bandaram Pharma, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi. In terms of performance, Centenial Surgic has a 1-year return of 27.99%, higher than KMS Medisurgi's 0.00%, while Poly Medicure leads with a 24.29% return.

Peers: The peers of Centenial Surgic are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Bandaram Pharma, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average or Average management risk. Growth is Excellent at Bandaram Pharma, Average at Poly Medicure and Indegene, and Below Average at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Centenial Surgic, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, and Vijaya Diagnost., while Good is found at Centenial Surgic, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.29%, while KMS Medisurgi has the lowest at 0.00%. Centenial Surgic's 1-year return of 27.99% is higher than both. Additionally, Bandaram Pharma, Tejnaksh Health., GKB Ophthalmics, and KMS Medisurgi have negative six-month returns.

View full answer

Is Centenial Surgic overvalued or undervalued?

09-Jun-2025

As of May 30, 2025, Centenial Surgic is considered very attractive and undervalued with a PE ratio of -32.38, an EV to EBITDA of 10.18, and a Price to Book Value of 1.68, especially when compared to competitors like Max Healthcare and Apollo Hospitals, while also boasting a strong 1-year stock return of 40.95%.

As of 30 May 2025, the valuation grade for Centenial Surgic has moved from very expensive to very attractive, indicating a significant shift in its market perception. The company appears to be undervalued, especially when considering its current PE ratio of -32.38, an EV to EBITDA of 10.18, and a Price to Book Value of 1.68. These figures suggest that despite the negative earnings reflected in the PE ratio, the company's valuation metrics are more favorable compared to its peers.<BR><BR>In comparison to notable competitors, Max Healthcare has a PE ratio of 100.29 and an EV to EBITDA of 62.71, while Apollo Hospitals shows a PE of 69.03 and an EV to EBITDA of 34.71. This stark contrast highlights Centenial Surgic's attractive valuation relative to its peers in the healthcare services industry. Additionally, the company's strong stock performance, with a 1-year return of 40.95% compared to the Sensex's 7.62%, reinforces the narrative that it is currently undervalued in the market.

View full answer

What is the technical trend for Centenial Surgic?

09-Jun-2025

As of June 6, 2025, Centennial Surgic's technical trend is mildly bullish, supported by the weekly MACD and Bollinger Bands, although caution is advised due to mixed signals from the monthly indicators and short-term bearishness in daily moving averages.

As of 6 June 2025, the technical trend for Centenial Surgic has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bearish, indicating some caution. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the upward momentum. The Dow Theory also shows a mildly bullish stance on both weekly and monthly charts. However, the daily moving averages are mildly bearish, suggesting short-term weakness. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some mixed signals from the monthly indicators.

View full answer

How big is Centenial Surgic?

24-Jul-2025

As of 24th July, Centenial Surgical Suture Ltd has a market capitalization of 54.00 Cr, with recent net sales totaling 53.52 Cr and a net profit loss of 1.60 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Centenial Surgical Suture Ltd has a market capitalization of 54.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 53.52 Cr, while the sum of Net Profit for the same period reflects a loss of 1.60 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 30.75 Cr and Total Assets valued at 84.55 Cr.

View full answer

How has been the historical performance of Centenial Surgic?

02-Dec-2025

Centenial Surgic's historical performance shows fluctuating net sales, increasing from 51.19 Cr in Mar'24 to 53.52 Cr in Mar'25, but it reported a loss with a profit after tax of -1.46 Cr in Mar'25, despite improved operating efficiency and cash flow from operations. Total liabilities and assets rose to 84.55 Cr in Mar'25, indicating financial challenges.

Answer:<BR>The historical performance of Centenial Surgic shows a fluctuating trend in net sales and profitability over the years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>Centenial Surgic's net sales increased from 51.19 Cr in Mar'24 to 53.52 Cr in Mar'25, following a dip in Mar'23. The total operating income also rose to 53.52 Cr in Mar'25 from 51.19 Cr in Mar'24. However, the company's total expenditure, excluding depreciation, increased slightly to 47.26 Cr in Mar'25 from 46.18 Cr in Mar'24. Operating profit, excluding other income, improved to 6.26 Cr in Mar'25 from 5.01 Cr in Mar'24, indicating better operational efficiency. Despite this, the company reported a profit before tax of -1.62 Cr in Mar'25, a decline from a profit of 1.27 Cr in Mar'24, leading to a profit after tax of -1.46 Cr in Mar'25 compared to 1.13 Cr in Mar'24. The total liabilities rose to 84.55 Cr in Mar'25 from 79.15 Cr in Mar'24, while total assets also increased to 84.55 Cr in Mar'25 from 79.15 Cr in Mar'24. The cash flow from operating activities improved to 17.00 Cr in Mar'25 from 6.00 Cr in Mar'24, but cash flow from investing activities was negative at -11.00 Cr. Overall, the company faced challenges in profitability despite an increase in sales and operating income.

View full answer

When is the next results date for Centenial Surgical Suture Ltd?

10-Feb-2026

The next results date for Centenial Surgical Suture Ltd is February 12, 2026.

The next results date for Centenial Surgical Suture Ltd is scheduled for February 12, 2026.

View full answer

Are Centenial Surgical Suture Ltd latest results good or bad?

14-Feb-2026

Centenial Surgical Suture Ltd's Q3 FY26 results show a net profit of ₹0.15 crore and a 21.80% revenue increase, indicating some recovery. However, concerns remain due to negative return on equity and poor stock performance compared to peers, suggesting investors should be cautious.

Centenial Surgical Suture Ltd's latest results for Q3 FY26 indicate a mixed performance. On the positive side, the company reported a net profit of ₹0.15 crore, marking a significant turnaround from a loss of ₹0.85 crore in the same quarter last year. Additionally, revenue grew by 21.80% year-on-year to ₹14.86 crore, which is the highest quarterly revenue in recent periods, and the operating margin improved to 10.30%.<BR><BR>However, despite these positive indicators, there are significant concerns regarding the company's overall financial health. The return on equity remains negative at -6.78%, and the five-year EBIT growth rate is troubling at -21.26%. The company's stock has also underperformed compared to its peers in the healthcare sector, declining 16.04% over the past year while the sector gained 25.64%.<BR><BR>In summary, while the latest quarterly results show some signs of recovery, the underlying issues related to profitability, capital efficiency, and market performance suggest that the company still faces substantial challenges. Investors may want to approach with caution given these mixed signals.

View full answer

Should I buy, sell or hold Centenial Surgical Suture Ltd?

15-Feb-2026

Why is Centenial Surgical Suture Ltd falling/rising?

17-Mar-2026

As of 17-Mar, Centenial Surgical Suture Ltd's stock price is rising to 89.30, indicating a potential shift in market sentiment after two days of decline. Increased investor participation and a significant rise in delivery volume suggest positive momentum, although the stock remains below its longer-term moving averages.

As of 17-Mar, Centenial Surgical Suture Ltd's stock price is rising, currently at 89.30, with a change of 1.57 (1.79%) upward. This increase follows a trend reversal after two consecutive days of decline, indicating a potential shift in market sentiment. Additionally, the stock has outperformed its sector by 1.24% today, suggesting stronger relative performance compared to its peers.<BR><BR>Investor participation has also increased, with a delivery volume of 366 on 16 March, which is a significant rise of 143.03% compared to the 5-day average delivery volume. This heightened interest from investors may be contributing to the upward movement in the stock price. However, it is important to note that the stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating that it has not yet regained a longer-term bullish trend. Despite this, the immediate performance and increased trading activity suggest a positive shift in the stock's trajectory.

View full answer

Why is Centenial Surgical Suture Ltd falling/rising?

18-Mar-2026

As of 18-Mar, Centenial Surgical Suture Ltd's stock price is at 87.00, reflecting a decline of 1.66%. The stock has underperformed against the benchmark Sensex and has shown significant losses over the past week, month, and year-to-date, indicating a bearish trend and decreased investor confidence.

As of 18-Mar, Centenial Surgical Suture Ltd's stock price is falling, currently at 87.00, which reflects a decrease of 1.47 or 1.66%. The stock has underperformed compared to the benchmark Sensex, with a performance today that is 2.96% lower than its sector. Over the past week, the stock has declined by 7.27%, and it has also shown significant losses over the past month and year-to-date, with declines of 13.00% and 15.37%, respectively. <BR><BR>Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Investor participation has also decreased, with delivery volume on 17 March falling by 66.42% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors, contributing to the stock's downward movement. Overall, these factors collectively explain the current decline in Centenial Surgical Suture Ltd's stock price.

View full answer

Why is Centenial Surgical Suture Ltd falling/rising?

19-Mar-2026

As of 19-Mar, Centenial Surgical Suture Ltd's stock price is at 87.00, unchanged from the previous day, with significant declines over various periods, including a 20.15% drop in the past week. Despite outperforming its sector today, the stock is trading below all moving averages and has seen a drastic decrease in investor participation.

As of 19-Mar, Centenial Surgical Suture Ltd's stock price is currently at 87.00, with no change from the previous day. The stock has experienced a significant decline over various periods, including a 20.15% drop over the past week and a 13.00% decrease over the past month. Year-to-date, the stock is down 15.37%, and it has also fallen 12.08% over the past year. <BR><BR>Despite these declines, the stock has outperformed its sector today by 2.82%. However, it is trading lower than its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, investor participation has decreased significantly, with a delivery volume of only 7 on March 18, which is a 95.6% drop compared to the 5-day average. The overall action in the Hospital & Healthcare Services sector has also been negative, with a decline of 2.8%. <BR><BR>These factors indicate that while there may be some short-term outperformance, the overall trend for Centenial Surgical Suture Ltd is downward, driven by significant declines in stock performance over multiple time frames and reduced investor activity.

View full answer

Why is Centenial Surgical Suture Ltd falling/rising?

20-Mar-2026

As of 20-Mar, Centenial Surgical Suture Ltd's stock price is at 87.00, showing a minor increase but significant declines over various periods, including an 18.68% drop in the past week. The stock is underperforming the market, trading below moving averages, and experiencing reduced investor participation, indicating bearish trends.

As of 20-Mar, Centenial Surgical Suture Ltd's stock price is currently at 87.00, reflecting a slight increase of 0.01 (0.01%). Despite this minor uptick, the stock has shown significant declines over various periods, including a 1-week drop of 18.68% and a year-to-date decrease of 15.37%. <BR><BR>The stock is underperforming compared to the broader market, as evidenced by its performance relative to the Sensex, which has only fallen by 0.04% over the past week. Additionally, the stock is trading below its moving averages across multiple time frames, indicating a bearish trend. <BR><BR>Investor participation has also diminished, with delivery volume on March 18 dropping by 95.6% compared to the 5-day average, suggesting a lack of confidence among investors. Furthermore, the Hospital & Healthcare Services sector has experienced a decline of 2.8%, which may be impacting Centenial Surgical Suture Ltd negatively. <BR><BR>Overall, while there is a slight increase in the stock price today, the broader trends and metrics indicate that the stock is facing significant downward pressure.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with a -12.72% CAGR growth in Operating Profits over the last 5 years

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.27
  • The company has been able to generate a Return on Equity (avg) of 2.19% signifying low profitability per unit of shareholders funds
2

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 32 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

55

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.33

stock-summary
Return on Equity

-3.52%

stock-summary
Price to Book

1.03

Revenue and Profits:
Net Sales:
15 Cr
(Quarterly Results - Dec 2025)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.67%
0%
-18.67%
6 Months
-23.08%
0%
-23.08%
1 Year
-20.43%
0%
-20.43%
2 Years
-9.53%
0%
-9.53%
3 Years
50.73%
0%
50.73%
4 Years
28.61%
0%
28.61%
5 Years
74.23%
0%
74.23%

Centenial Surgic for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Centenial Surgical Suture Ltd Surges 20.49%: Key Financial Turnaround and Technical Shifts

Announcements stock-summary

Clarification On Price Movement

17-Mar-2026 | Source : BSE

PFA

Clarification sought from Centenial Surgical Suture Ltd

13-Mar-2026 | Source : BSE

The Exchange has sought clarification from Centenial Surgical Suture Ltd on March 13 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.

The reply is awaited.

Urgent Attention For Possible MISUSE / UNETHICAL / UNUSUAL TRADES In Our Company Scrip.

17-Feb-2026 | Source : BSE

PFA

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
8.51%
EBIT Growth (5y)
-12.72%
EBIT to Interest (avg)
1.27
Debt to EBITDA (avg)
1.97
Net Debt to Equity (avg)
0.33
Sales to Capital Employed (avg)
1.53
Tax Ratio
8.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.60%
ROE (avg)
2.19%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
55
Price to Book Value
1.00
EV to EBIT
20.64
EV to EBITDA
6.59
EV to Capital Employed
1.00
EV to Sales
0.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2.81%
ROE (Latest)
-3.52%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Vijay Kalidas Majrekar (22.62%)

Highest Public shareholder

Kartik Shyam Kingar (16.7%)

Individual Investors Holdings

50.7%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 21.80% vs -1.45% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 117.65% vs -374.19% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14.86",
          "val2": "12.20",
          "chgp": "21.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.53",
          "val2": "0.76",
          "chgp": "101.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.35",
          "val2": "0.50",
          "chgp": "-30.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.15",
          "val2": "-0.85",
          "chgp": "117.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "10.30%",
          "val2": "6.23%",
          "chgp": "4.07%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is -34.37% vs 43.56% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 82.14% vs -166.67% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "26.39",
          "val2": "40.21",
          "chgp": "-34.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.62",
          "val2": "4.19",
          "chgp": "-37.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.78",
          "val2": "1.55",
          "chgp": "-49.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.05",
          "val2": "-0.28",
          "chgp": "82.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "9.93%",
          "val2": "10.42%",
          "chgp": "-0.49%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 2.59% vs 2.73% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 123.26% vs -151.19% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "41.25",
          "val2": "40.21",
          "chgp": "2.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.15",
          "val2": "4.20",
          "chgp": "-1.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.13",
          "val2": "1.56",
          "chgp": "-27.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.10",
          "val2": "-0.43",
          "chgp": "123.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "10.06%",
          "val2": "10.45%",
          "chgp": "-0.39%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 4.55% vs -2.79% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -229.20% vs 13.00% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "53.52",
          "val2": "51.19",
          "chgp": "4.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6.26",
          "val2": "5.01",
          "chgp": "24.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.75",
          "val2": "2.47",
          "chgp": "51.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-1.46",
          "val2": "1.13",
          "chgp": "-229.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.70%",
          "val2": "9.79%",
          "chgp": "1.91%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
14.86
12.20
21.80%
Operating Profit (PBDIT) excl Other Income
1.53
0.76
101.32%
Interest
0.35
0.50
-30.00%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.15
-0.85
117.65%
Operating Profit Margin (Excl OI)
10.30%
6.23%
4.07%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is 21.80% vs -1.45% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in quarter ended Dec 2025 is 117.65% vs -374.19% in Dec 2024

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Mar'25
Change(%)
Net Sales
26.39
40.21
-34.37%
Operating Profit (PBDIT) excl Other Income
2.62
4.19
-37.47%
Interest
0.78
1.55
-49.68%
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.05
-0.28
82.14%
Operating Profit Margin (Excl OI)
9.93%
10.42%
-0.49%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is -34.37% vs 43.56% in Mar 2025

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is 82.14% vs -166.67% in Mar 2025

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
41.25
40.21
2.59%
Operating Profit (PBDIT) excl Other Income
4.15
4.20
-1.19%
Interest
1.13
1.56
-27.56%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.10
-0.43
123.26%
Operating Profit Margin (Excl OI)
10.06%
10.45%
-0.39%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 2.59% vs 2.73% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is 123.26% vs -151.19% in Dec 2024

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
53.52
51.19
4.55%
Operating Profit (PBDIT) excl Other Income
6.26
5.01
24.95%
Interest
3.75
2.47
51.82%
Exceptional Items
0.00
0.00
Standalone Net Profit
-1.46
1.13
-229.20%
Operating Profit Margin (Excl OI)
11.70%
9.79%
1.91%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 4.55% vs -2.79% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is -229.20% vs 13.00% in Mar 2024

stock-summaryCompany CV
About Centenial Surgical Suture Ltd stock-summary
stock-summary
Centenial Surgical Suture Ltd
Micro Cap
Healthcare Services
Incorporated in 1995, Centenial Surgical Suture is engaged in the manufacture and sale of surgical sutures in India. The company offers absorbable sutures that include natural and synthetic sutures and non absorbable sutures comprising needles for cardiovascular surgery, monofilament polyamide atraumatic needle suture combinations, monofilament stainless steel, and temporary pacemaker electrodes.
Company Coordinates stock-summary
Company Details
Plot No F-29, MIDC Industrial Area Murbad Thane Maharashtra : 421401
stock-summary
Tel: 91-2524-222905/222906
stock-summary
admin@centenialindia.com
Registrar Details
Purva Shareregistry (India) Pvt Ltd , Gala No 9, Shiv Shakti, Industrial Estate,Sitaram Mill Comp., J R Boricha Marg, Lower Parel [E], Mumbai